Insider Selling: Outset Medical, Inc. (NASDAQ:OM) CEO Sells $13,149.90 in Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 14,611 shares of Outset Medical stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $0.90, for a total value of $13,149.90. Following the completion of the sale, the chief executive officer now directly owns 880,969 shares of the company’s stock, valued at approximately $792,872.10. This trade represents a 1.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Leslie Trigg also recently made the following trade(s):

• On Tuesday, January 21st, Leslie Trigg sold 65,236 shares of Outset Medical stock. The stock was sold at an average price of $0.80, for a total transaction of $52,188.80.
• On Monday, January 13th, Leslie Trigg sold 33,227 shares of Outset Medical stock. The shares were sold at an average price of $0.81, for a total value of $26,913.87.
• On Tuesday, January 7th, Leslie Trigg sold 10,227 shares of Outset Medical stock. The stock was sold at an average price of $1.29, for a total value of $13,192.83.

Outset Medical Stock Performance

NASDAQ OM opened at $0.88 on Friday. The company has a debt-to-equity ratio of 4.12, a quick ratio of 5.04 and a current ratio of 6.49. Outset Medical, Inc. has a 12 month low of $0.44 and a 12 month high of $5.22. The company’s 50 day moving average is $0.95 and its two-hundred day moving average is $0.83.

Outset Medical (NASDAQ:OM) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). The business had revenue of $29.47 million for the quarter, compared to the consensus estimate of $28.47 million. Outset Medical had a negative net margin of 112.57% and a negative return on equity of 175.64%. As a group, equities research analysts expect that Outset Medical, Inc. will post -1.99 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Royal Bank of Canada reiterated a “sector perform” rating and issued a $3.00 price objective on shares of Outset Medical in a research report on Tuesday, January 7th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of OM. GSA Capital Partners LLP raised its holdings in shares of Outset Medical by 924.7% in the 3rd quarter. GSA Capital Partners LLP now owns 1,111,612 shares of the company’s stock valued at $753,000 after purchasing an additional 1,003,135 shares in the last quarter. Huntington National Bank increased its holdings in shares of Outset Medical by 46.2% in the third quarter. Huntington National Bank now owns 63,306 shares of the company’s stock valued at $43,000 after purchasing an additional 20,000 shares during the period. National Bank of Canada FI grew its stake in shares of Outset Medical by 79.2% during the 3rd quarter. National Bank of Canada FI now owns 52,407 shares of the company’s stock worth $35,000 after purchasing an additional 23,164 shares during the period. Renaissance Technologies LLC grew its position in shares of Outset Medical by 1,167.7% during the 4th quarter. Renaissance Technologies LLC now owns 686,748 shares of the company’s stock valued at $762,000 after acquiring an additional 632,574 shares during the period. Finally, XTX Topco Ltd purchased a new stake in shares of Outset Medical in the fourth quarter valued at approximately $50,000.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.